Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs

Stem Cell Research and Therapy

Volumn 7, Issue 1, 2016, Pages

  Bazhanov, Nikolay ^a   Ylostalo, Joni H ^a   Bartosh, Thomas J ^a   Tiblow, April ^a   Mohammadipoor, Arezoo ^a   Foskett, Andrea ^a   Prockop, Darwin J ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Cell tracking; Cytokines; Intraperitoneal injections; Mesenchymal stem cells; MSC

Indexed keywords

CD45 ANTIGEN; GREEN FLUORESCENT PROTEIN; CYTOKINE; LIPOPOLYSACCHARIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL AGGREGATION; CELL FATE; CELL LABELING; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GAPDH GENE; GENE; HUMAN; HUMAN CELL; IN VIVO STUDY; INJECTION; LYMPH NODE; LYMPHOCYTE; MACROPHAGE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENTERY; MOUSE; NONHUMAN; OMENTUM; PERITONEAL CAVITY; PERITONEUM; PERITONEUM LAVAGE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CYTOLOGY; IMMUNOLOGY; MESENCHYMAL STROMA CELL; METABOLISM; PARENTERAL DRUG ADMINISTRATION; PERITONEUM MACROPHAGE; PHYSIOLOGY; SECRETION (PROCESS);

ANIMALS; ANTIGENS, CD45; CELL ADHESION; CELL AGGREGATION; CYTOKINES; HUMANS; INFUSIONS, PARENTERAL; LIPOPOLYSACCHARIDES; LYMPHOCYTES; MACROPHAGES, PERITONEAL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; PERITONEUM;

EID: 84957588494     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-016-0284-5     Document Type: Article

References (41)

1. Clinicaltrials.gov. US National Institutes of Health. https://www.clinicaltrials.gov. Accessed 02 Feb 2016.
2. Syed BA, Evans JB. Stem cell therapy market. Nat Rev Drug Discov. 2013;12:185-6.
3. Waterman RS, Henkle SL, Betancourt AM. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One. 2012;7:e45590.
4. Dembinski JL, Wilson SM, Spaeth EL, Studeny M, Zompetta C, Samudio I, et al. Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer. Cytotherapy. 2013;15:20-32.
5. Eliopoulos N, Zhao J, Bouchentouf M, Forner K, Birman E, Yuan S, et al. Human marrow-derived mesenchymal stromal cells decrease cisplatin renotoxicity in vitro and in vivo and enhance survival of mice post-intraperitoneal injection. Am J Physiol Renal Physiol. 2010;299:F1288-98.
6. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169:12-20.
7. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5:54-63.
8. Yousefi F, Ebtekar M, Soleimani M, Soudi S, Hashemi SM. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol. 2013;17:608-16.
9. Scruggs BA, Zhang X, Bowles AC, Gold PA, Semon JA, Fisher-Perkins JM, et al. Multipotent stromal cells alleviate inflammation, neuropathology, and symptoms associated with globoid cell leukodystrophy in the twitcher mouse. Stem Cells. 2013;31:1523-34.
10. Cheng K, Rai P, Plagov A, Lan X, Kumar D, Salhan D, et al. Transplantation of bone marrow-derived MSCs improves cisplatinum-induced renal injury through paracrine mechanisms. Exp Mol Pathol. 2013;94:466-73.
11. Castelo-Branco MTL, Soares IDP, Lopes DV, Buongusto F, Martinusso CA, Do Rosario A, et al. Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS One. 2012;7:e33360.
12. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Ylostalo J, Coble K, et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-α stimulated gene/protein 6. Stem Cells. 2011;29:1572-9.
13. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kB signaling in resident macrophages. Blood. 2011;118:330-8.
14. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell. 2012;10:709-16.
15. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. Mol Ther. 2012;20:14-20.
16. Stommel MW, Strik C, van Goor H. Response to pathological processes in the peritoneal cavity - sepsis, tumours, adhesions, and ascites. Semin Pediatr Surg. 2014;23:331-5.
17. Melichar B, Freedman RS. Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer. 2002;12:3-17.
18. Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity. 2005;23:7-18.
19. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463:540-4.
20. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464:1367-70.
21. Saenz SA, Siracusa MC, Perrigoue JG, Spencer SP, Urban JF, Tocker JE, et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature. 2010;464:1362-6.
22. Price AE, Liang H, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A. 2010;107:11489-94.
23. Allen JE, Maizels RM. Diversity and dialogue in immunity to helminths. Nat Rev Immunol. 2011;11:375-88.
24. Rangel-Moreno J, Moyron-Quiroz JE, Carragher DM, Kusser K, Hartson L, Moquin A, et al. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens. Immunity. 2009;30:731-43.
25. Carlow DA, Gold MR, Ziltener HJ. Lymphocytes in the peritoneum home to the omentum and are activated by resident dendritic cells. J Immunol. 2009;183:1155-65.
26. Abu-Hijleh MF, Habbal OA, Moqattash ST. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat. 1995;186(Pt 3):453-67.
27. Nakatani T, Tanaka S, Mizukami S, Okamoto K, Shiraishi Y, Nakamura T. Peritoneal lymphatic stomata of the diaphragm in the mouse: process of their formation. Anat Rec. 1997;248:121-8.
28. Wilson T, Stark C, Holmbom J, Rosling A, Kuusilehto A, Tirri T, et al. Fate of bone marrow-derived stromal cells after intraperitoneal infusion or implantation into femoral bone defects in the host animal. J Tissue Engineering. 2010;345806.
29. Meyerrose TE, De Ugarte DA, Hofling AA, Herrbrich PE, Cordonnier TD, Shultz LD, et al. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells. 2007;25:220-7.
30. Bartosh TJ, Ylostalo JH, Bazhanov N, Kuhlman J, Prockop DJ. Dynamic compaction of human mesenchymal stem/precursor cells into spheres self-activates caspase-dependent il1 signaling to enhance secretion of modulators of inflammation and immunity (PGE2, TSG6, and STC1). Stem Cells. 2013;31:2443-56.
31. Turley SJ, Lee J, Dutton-Swain N, Mathis D, Benoist C. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc Natl Acad Sci U S A. 2005;102:17729-33.
32. Center for the Preparation and Distribution of Adult Stem Cells. Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White. http://www.medicine.tamhsc.edu/irm/msc-distribution.html. Accessed 30 June 2014.
33. Ylostalo J, Bazhanov N, Prockop DJ. Reversible commitment to differentiation by human multipotent stromal cells in single-cell-derived colonies. Exp Hematol. 2008;36:1390-402.
34. Reger RL, Prockop DJ. Should publications on mesenchymal stem/progenitor cells include in-process data on the preparation of the cells? Stem Cells Translational Med. 2014;3:632-5.
35. Phinney DG. Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. Cell Cycle. 2007;6:2884-9.
36. Lee RH, Yu JM, Foskett AM, Peltier G, Reneau JC, Bazhanov N, et al. TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo. Proc Natl Acad Sci U S A. 2014;111:16766-71.
37. Ylostalo JH, Bartosh TJ, Coble K, Prockop DJ. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells. 2012;30:2283-96.
38. Oh JY, Roddy GW, Choi H, Lee RH, Ylostalo JH, Rosa RH, et al. Anti-inflammatory protein TSG-6 reduces inflammatory damage to the cornea following chemical and mechanical injury. Proc Natl Acad Sci U S A. 2010;107:16875-80.
39. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther. 2004;9:747-56.
40. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 2007;25:371-9.
41. Boregowda SV, Krishnappa V, Chambers JW, Lograsso PV, Lai WT, Ortiz LA, et al. Atmospheric oxygen inhibits growth and differentiation of marrow-derived mouse mesenchymal stem cells via a p53-dependent mechanism: Implications for long-term culture expansion. Stem Cells. 2012;30:975-87.